34 / 46
Plasma AR status is associated with worse outcome
to enzalutamide
-50
0
50
100
D
B
C
A
Prostate-specific antigen change (%)
Overall survival (%)
PSA Progression-free survival (%)
0
3
6
9
12
0
50
100
Months
0
3
6
9
12
0
50
100
Months
50
100
RAD Progression-free survival (%)
AR
Normal
AR
Gain
83
82
(1)
59
(18)
38
(6)
22
(2)
11
9
(2)
3
(6)
1
(0)
0
(0)
AR
Normal
Number at risk
AR
Gain
83
79
(3)
70
(4)
48
(5)
29
(1)
11
9
(2)
4
(5)
2
(1)
0
(0)
AR
Normal
Number at risk
AR
Gain
AR
Normal
AR
Gain
FIGURE 2
2b.
-50
0
50
100
D
B
C
A
rostate-specific antigen change (%)
Overall survival (%)
PSA Progression-free survival (%)
0
3
6
9
12
0
50
100
Months
0
3
6
9
12
0
50
100
Months
50
100
RAD Progression-free survival (%)
AR
Normal
AR
Gain
83
82
(1)
59
(18)
38
(6)
22
(2)
1
9
(2)
3
(6)
1
(0)
0
(0)
AR
Normal
Number at risk
AR
Gain
83
79
(3)
70
(4)
48
(5)
29
(1)
11
9
(2)
4
(5)
2
(1)
0
(0)
AR
Normal
Numbe at risk
AR
Gain
AR
Normal
AR
Gain
FIGURE 2
2c.
D
C
Prostate-specific antigen change (%)
Overall survival (%)
PSA Progr
0
3
6
9
12
0
Months
0
3
6
9
12
0
50
100
Months
AR
Normal
AR
Gain
83
82
(1)
59
(18)
38
(6)
22
(2)
11
9
(2)
3
(6)
1
(0)
0
(0)
AR
Normal
Number at risk
AR
Gain
83
81
(1)
76
(0)
55
(1)
32
(1)
11
11
(0)
8
(2)
4
(1)
0
(0)
AR
Normal
Number at risk
AR
Gain
Median sPFS: 3.60 versus 15.5 months
HR, 4.33; 95% CI 1.94-9.68; P < 0.001
Median rPFS: 3.90 months versus not reached
HR, 8.06; 95% CI, 3.26-19.93; P < 0.001
Median OS: medians not reached
HR, 11.08; 95% CI, 2.16-56.95; P = 0.004
Conteduca V & Grande E. Annals of Oncology 2017
PSA-PFS
Radiographic-PFS
Overall Survival